JP2024537394A - 修飾タンパク質およびタンパク質分解剤 - Google Patents

修飾タンパク質およびタンパク質分解剤 Download PDF

Info

Publication number
JP2024537394A
JP2024537394A JP2024522487A JP2024522487A JP2024537394A JP 2024537394 A JP2024537394 A JP 2024537394A JP 2024522487 A JP2024522487 A JP 2024522487A JP 2024522487 A JP2024522487 A JP 2024522487A JP 2024537394 A JP2024537394 A JP 2024537394A
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
optionally substituted
ceutically acceptable
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537394A5 (cg-RX-API-DMAC7.html
Inventor
リュー,ジン
ブルーノ プレーヴェ,マイケル
ハン,シャオラン
ジャン,チェンウェイ
ヤン,ティン
チェン,リクン
ランドルフ リー,マシュー
ジョー,ジン
ディン,ジエ
ワン,ジアリャン
Original Assignee
クルゲン(シャンハイ),インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クルゲン(シャンハイ),インク. filed Critical クルゲン(シャンハイ),インク.
Publication of JP2024537394A publication Critical patent/JP2024537394A/ja
Publication of JP2024537394A5 publication Critical patent/JP2024537394A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024522487A 2021-10-14 2022-10-13 修飾タンパク質およびタンパク質分解剤 Pending JP2024537394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021123848 2021-10-14
CNPCT/CN2021/123848 2021-10-14
CNPCT/CN2021/133363 2021-11-26
CN2021133363 2021-11-26
PCT/CN2022/125080 WO2023061440A1 (en) 2021-10-14 2022-10-13 Modified proteins and protein degraders

Publications (2)

Publication Number Publication Date
JP2024537394A true JP2024537394A (ja) 2024-10-10
JP2024537394A5 JP2024537394A5 (cg-RX-API-DMAC7.html) 2025-10-21

Family

ID=85987275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522487A Pending JP2024537394A (ja) 2021-10-14 2022-10-13 修飾タンパク質およびタンパク質分解剤

Country Status (9)

Country Link
US (1) US20250235543A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416145A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537394A (cg-RX-API-DMAC7.html)
CN (1) CN118451078A (cg-RX-API-DMAC7.html)
AU (1) AU2022362494A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234615A1 (cg-RX-API-DMAC7.html)
IL (1) IL312013A (cg-RX-API-DMAC7.html)
MX (1) MX2024004525A (cg-RX-API-DMAC7.html)
WO (1) WO2023061440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
WO2024072794A1 (en) * 2022-09-26 2024-04-04 Rectify Pharmaceuticals, Inc. Pyridine carboxamide compounds and their use in treating medical conditions
CN121005703A (zh) * 2024-05-24 2025-11-25 中国科学院广州生物医药与健康研究院 一种酰胺吲嗪类化合物及其制备方法和应用
WO2026107421A1 (en) * 2024-11-18 2026-05-21 Bristol-Myers Squibb Company 1 h-benzo[d]imidazole derivatives as camk2 inhibitors for the treatment of heart failure

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119357A1 (en) * 2016-12-24 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
JP2019514883A (ja) * 2016-04-22 2019-06-06 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド サイクリン依存性キナーゼ4/6(cdk4/6)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるcdk4/6の分解および使用法
JP2020514252A (ja) * 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Cdk4/6媒介性がんを治療するための組成物および方法
WO2020207396A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
WO2021061151A1 (en) * 2019-09-27 2021-04-01 Romark Laboratories L.C. Screening for anti-hepatitis b compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201522337A (zh) * 2013-03-12 2015-06-16 Arqule Inc 經取代之三環吡唑並-嘧啶化合物類
CA3103185A1 (en) * 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
WO2020092662A1 (en) * 2018-11-02 2020-05-07 The Wistar Institute Of Anatomy And Biology Proteolysis-targeting chimeras
EA202192260A1 (ru) * 2019-02-15 2021-12-17 Инсайт Корпорейшн Биомаркеры циклин-зависимой киназы 2 и их применение
CN113646002A (zh) * 2019-02-27 2021-11-12 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
JP2022529700A (ja) * 2019-04-23 2022-06-23 ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド サイクリン依存性キナーゼ12(cdk12)の分解剤およびその使用
CN112409376A (zh) * 2019-08-20 2021-02-26 华东师范大学 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用
CN114502534A (zh) * 2019-09-30 2022-05-13 协和麒麟株式会社 Bet降解剂
WO2021239117A1 (en) * 2020-05-28 2021-12-02 Cullgen (Shanghai) , Inc. Modified proteins and protein degraders
CN116507333B (zh) * 2020-08-27 2025-05-09 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
TW202423914A (zh) * 2022-08-19 2024-06-16 美商凱麥拉醫療公司 Cdk2降解劑及其用途
US20240174665A1 (en) * 2022-08-19 2024-05-30 Kymera Therapeutics, Inc. Cdk2 inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019514883A (ja) * 2016-04-22 2019-06-06 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド サイクリン依存性キナーゼ4/6(cdk4/6)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるcdk4/6の分解および使用法
JP2020514252A (ja) * 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Cdk4/6媒介性がんを治療するための組成物および方法
WO2018119357A1 (en) * 2016-12-24 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
WO2020207396A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
WO2021061151A1 (en) * 2019-09-27 2021-04-01 Romark Laboratories L.C. Screening for anti-hepatitis b compounds

Also Published As

Publication number Publication date
CN118451078A (zh) 2024-08-06
AU2022362494A1 (en) 2024-05-23
EP4416145A4 (en) 2026-05-27
CA3234615A1 (en) 2023-04-20
MX2024004525A (es) 2024-05-24
WO2023061440A1 (en) 2023-04-20
IL312013A (en) 2024-06-01
EP4416145A1 (en) 2024-08-21
US20250235543A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
US11884680B2 (en) Bromodomain inhibitors
US20250235543A1 (en) Modified proteins and protein degraders
TWI770527B (zh) Cot 調節劑及其使用方法
CN109071552B (zh) 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法
AU2013305634B2 (en) Novel 4,6-disubstituted aminopyrimidine derivatives
BG106678A (bg) ПИРАЗОЛО [4,3 - d] ПИРИМИДИНОВИ ПРОИЗВОДНИ
AU2023271807A1 (en) Inhibitors of parg
WO2009085256A1 (en) Anti-hiv compounds
JP2017515848A (ja) タンパク質脱アセチル化酵素阻害剤およびタンパク質脱アセチル化酵素−タンパク質キナーゼ二重阻害剤としての複素環式ヒドロキサム酸ならびにその使用方法
JP6797923B2 (ja) Alkおよびsrpk阻害剤ならびに使用方法
CN108463222A (zh) 用于治疗疾病的杂环化合物
JP4721452B2 (ja) Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2008501618A6 (ja) Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2025500871A (ja) ピリミジン又はピリジン誘導体及びその医薬用途
CN107743489A (zh) 用于治疗免疫疾病、炎性疾病或者癌症的7‑(吗啉‑4‑基)吡唑并[1,5‑a]嘧啶衍生物
CN115996911A (zh) 具有p2x4受体拮抗活性的取代的n-苯乙酰胺
JP2024516194A (ja) Pd1/pd-l1阻害剤としての化合物及びその方法
WO2004101567A1 (en) 2-SUBSTITUTED PHENYL -6,8-DIALKYL-3H-IMIDAZOLE [1,5a][1,3,5] TRIAZINE -4- ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF
HK1229722B (en) Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251010

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260805